CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health or via the ISPOR Health Economic Evaluation Publication Guidelines - CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

Section/item	Item No	Recommendation	Reported on page No/ line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.	Page 1 / Title page
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	Pages 2-3
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or	Dogo F
		practice decisions.	Page 5
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Pages 5-7
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Pages 5-7
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Page 10
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Pages 8-9
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Page 9, 10
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Not appropriate
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Page 10
Measurement of effectiveness	11a	Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	Pages 6-7



	11b	Synthesis-based estimates: Describe fully the methods used for	
		identification of included studies and synthesis of clinical	
Massymanantand	12	effectiveness data.	
Measurement and	12	If applicable, describe the population and methods used to	
valuation of preference based outcomes		elicit preferences for outcomes.	Pages 6-7
Estimating resources	13a	Single study-based economic evaluation: Describe approaches	
and costs		used to estimate resource use associated with the alternative	
		interventions. Describe primary or secondary research methods	
		for valuing each resource item in terms of its unit cost.	
		Describe any adjustments made to approximate to opportunity	
		costs.	
	13b	Model-based economic evaluation: Describe approaches and	
		data sources used to estimate resource use associated with	
		model health states. Describe primary or secondary research	
		methods for valuing each resource item in terms of its unit	
		cost. Describe any adjustments made to approximate to	Page 8; Supplement page 65
Cyman ay maiga data	1.4	opportunity costs.	
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to	
and conversion		the year of reported costs if necessary. Describe methods for	
		converting costs into a common currency base and the	
		exchange rate.	Page 8
Choice of model	15	Describe and give reasons for the specific type of decision-	
		analytical model used. Providing a figure to show model	Page 14;
		structure is strongly recommended.	Figure 1
Assumptions	16	Describe all structural or other assumptions underpinning the	Pages 8-10;
		decision-analytical model.	Supplement
Analytical methods	17	Describe all analytical methods supporting the evaluation. This	
		could include methods for dealing with skewed, missing, or	
		censored data; extrapolation methods; methods for pooling	
		data; approaches to validate or make adjustments (such as half	
		•	Pages 8-10; Suppl. pages 65-67; 78
		population heterogeneity and uncertainty.	
Results			
Study parameters	18	Report the values, ranges, references, and, if used, probability	
		distributions for all parameters. Report reasons or sources for	Doggo 10 12:
		distributions used to represent uncertainty where appropriate.	Pages 10-13; Table 3;
		Providing a table to show the input values is strongly recommended.	Supplement
Incremental costs and	19	For each intervention, report mean values for the main	
outcomes	1)	categories of estimated costs and outcomes of interest, as well	
outcomes		as mean differences between the comparator groups. If	
		applicable, report incremental cost-effectiveness ratios.	Table 3
Characterising	20a	Single study-based economic evaluation: Describe the effects	Page 12;
uncertainty		of sampling uncertainty for the estimated incremental cost and	Supplement
		incremental effectiveness parameters, together with the impact	Suppl. pages 28, 80,81



	20b	of methodological assumptions (such as discount rate, study perspective). Model-based economic evaluation: Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost- effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	N/A
Discussion			
Study findings, limitations, generalisability, and	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with	Pages 13-16
current knowledge		current knowledge.	- agos 10 10
Other Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Page 18
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Pages 18-19

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the Value in Health link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.

